{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:08:42Z","timestamp":1791410922754,"version":"4.3.3"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T00:00:00Z","timestamp":1686009600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Pericardial effusion (PE) is an uncommon but serious complication that occurs following percutaneous left atrial appendage closure (LAAC). There are few data regarding PE following implantation of the LAmbre device for LAAC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients with nonvalvular atrial fibrillation (AF) undergoing percutaneous LAAC using the LAmbre device at the Arrhythmia Center of Ningbo First Hospital from October 2017 to March 2021 were retrospectively reviewed (<jats:italic>n\u2009<\/jats:italic>=\u2009133). PE was defined as acute if diagnosed \u22647 days post LAAC (<jats:italic>n\u2009<\/jats:italic>=\u20093, 2.3%) or delayed if diagnosed &amp;gt;7 days post LAAC (<jats:italic>n\u2009<\/jats:italic>=\u20093, 2.3%). The clinical characteristics and procedural data were compared between patients with PE (PE group, <jats:italic>n\u2009<\/jats:italic>=\u20096) and without PE (non-PE group, <jats:italic>n\u2009<\/jats:italic>=\u2009127). The predictors of PE were analyzed by logistic regression.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>All patients with PE recovered following treatment by pericardiocentesis. Patients with PE were found to have a higher incidence of congestive heart failure (50.0% vs. 13.4%, <jats:italic>P\u2009<\/jats:italic>=\u20090.044) and had larger measured LAA orifice diameters (33.5\u2005mm\u2009\u00b1\u20096.0\u2005mm vs. 28.3\u2005mm\u2009\u00b1\u20095.2\u2005mm, <jats:italic>P\u2009<\/jats:italic>=\u20090.018) and landing zone diameters (27.8\u2005mm\u2009\u00b1\u20094.8\u2005mm vs. 23.9\u2005mm\u2009\u00b1\u20094.8\u2005mm, <jats:italic>P\u2009<\/jats:italic>=\u20090.054) compared with those without PE. The diameters of the device umbrellas (31.7\u2005mm\u2009\u00b1\u20095.6\u2005mm vs. 26.9\u2005mm\u2009\u00b1\u20095.0\u2005mm, <jats:italic>P\u2009<\/jats:italic>=\u20090.026) and covers (36.3\u2005mm\u2009\u00b1\u20094.6\u2005mm vs. 33.4\u2005mm\u2009\u00b1\u20094.0\u2005mm, <jats:italic>P\u2009<\/jats:italic>=\u20090.075) implanted were larger in the PE group compared to the non-PE group. Univariate logistic regression revealed that congestive heart failure (OR\u2009=\u20096.47, 95% CI<jats:italic>\u2009<\/jats:italic>=\u20091.21\u201334.71, <jats:italic>P\u2009<\/jats:italic>=\u20090.029) and LAA maximal orifice diameter (OR\u2009=\u20091.22, 95% CI<jats:italic>\u2009<\/jats:italic>=\u20091.02\u20131.45, <jats:italic>P\u2009<\/jats:italic>=\u20090.027) were both associated with PE following LAmbre device implantation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In this single-center experience, both acute and delayed PE were uncommon in patients with AF following LAmbre device implantation. Congestive heart failure and a larger LAA orifice were identified as predictors for the occurrence of PE.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2023.1188322","type":"journal-article","created":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T10:48:30Z","timestamp":1695034110000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Pericardial effusion following percutaneous left atrial appendage closure using the LAmbre device"],"prefix":"10.3389","volume":"10","author":[{"given":"Yibo","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huimin","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binhao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guohua","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European association for cardio-thoracic surgery (EACTS)","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2964","DOI":"10.1016\/j.jacc.2017.10.021","article-title":"5-Year Outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF trials","volume":"70","author":"Reddy","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"3122","DOI":"10.1016\/j.jacc.2020.04.067","article-title":"Left atrial appendage closure versus direct oral anticoagulants in high-risk patients with atrial fibrillation","volume":"75","author":"Osmancik","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/joic.12502","article-title":"An updated systematic review and meta-analysis of early outcomes after left atrial appendage occlusion","volume":"31","author":"Yerasi","year":"2018","journal-title":"J Interv Cardiol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2022.11.010","article-title":"Delayed pericardial effusion or tamponade following left atrial appendage closure: a single-center experience","author":"Fu","year":"2022","journal-title":"J Formos Med Assoc"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1161\/CIRCULATIONAHA.121.057063","article-title":"Amplatzer amulet left atrial appendage occluder versus watchman device for stroke prophylaxis (amulet IDE): a randomized, controlled trial","volume":"144","author":"Lakkireddy","year":"2021","journal-title":"Circulation"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e011718","DOI":"10.1161\/CIRCINTERVENTIONS.121.011718","article-title":"Periprocedural pericardial effusion complicating transcatheter left atrial appendage occlusion: a report from the NCDR LAAO registry","volume":"15","author":"Price","year":"2022","journal-title":"Circ Cardiovasc Interventions"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1016\/j.hrthm.2021.05.017","article-title":"Pericardial effusion requiring intervention in patients undergoing percutaneous left atrial appendage occlusion: prevalence, predictors, and associated in-hospital adverse events from 17,700 procedures in the United States","volume":"18","author":"Munir","year":"2021","journal-title":"Heart Rhythm"},{"key":"B9","first-page":"E1","article-title":"Delayed pericardial effusion following left atrial appendage closure: a 5-year single-center experience","volume":"35","author":"Mogalapalli","year":"2023","journal-title":"J Invasive Cardiol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.amjcard.2021.08.028","article-title":"Incidence and outcomes of pericardial effusion\/tamponade following percutaneous left atrial appendage closure","volume":"160","author":"Isogai","year":"2021","journal-title":"Am J Cardiol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1111\/jce.13626","article-title":"Incidence of pericardial effusion after left atrial appendage closure: the impact of underlying heart rhythm-data from the EWOLUTION study","volume":"29","author":"Schmidt","year":"2018","journal-title":"J Cardiovasc Electrophysiol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1016\/j.jcin.2017.06.072","article-title":"Percutaneous left atrial appendage closure with the LAmbre device for stroke prevention in atrial fibrillation: a prospective, multicenter clinical study","volume":"10","author":"Huang","year":"2017","journal-title":"JACC Cardiovasc Interv"},{"key":"B13","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.ijcard.2018.02.120","article-title":"Left atrial appendage occlusion with lambre in atrial fibrillation: initial European experience","volume":"265","author":"Park","year":"2018","journal-title":"Int J Cardiol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1111\/jce.15020","article-title":"Delayed pericardial effusion after left atrial appendage closure with the LAmbre device: importance of a fully open umbrella","volume":"32","author":"Xiao","year":"2021","journal-title":"J Cardiovasc Electrophysiol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/s0895-4356(96)00236-3","article-title":"A simulation study of the number of events per variable in logistic regression analysis","volume":"49","author":"Peduzzi","year":"1996","journal-title":"J Clin Epidemiol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1002\/clc.23950","article-title":"Long-term safety and efficacy of left atrial appendage closure in patients with small appendage orifices measured with transesophageal echocardiography","volume":"46","author":"Wang","year":"2023","journal-title":"Clin Cardiol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e006841","DOI":"10.1161\/CIRCEP.118.006841","article-title":"Evaluating real-world clinical outcomes in atrial fibrillation patients receiving the WATCHMAN left atrial appendage closure technology: final 2-year outcome data of the EWOLUTION trial focusing on history of stroke and hemorrhage","volume":"12","author":"Boersma","year":"2019","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1111\/jce.14398","article-title":"Late clinical outcomes of lambre versus amplatzer occluders for left atrial appendage closure","volume":"31","author":"Schnupp","year":"2020","journal-title":"J Cardiovasc Electrophysiol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1007\/s10554-019-01625-6","article-title":"Left atrial appendage orifice diameter measured with trans-esophageal echocardiography is independently related with peri-device leakage after Watchman device implantation","volume":"35","author":"Chen","year":"2019","journal-title":"Int J Cardiovasc Imaging"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1002\/clc.23073","article-title":"Sex-related differences in left ventricular diastolic function and arterial elastance during admission in patients with heart failure with preserved ejection fraction: the PURSUIT HfpEF study","volume":"41","author":"Hoshida","year":"2018","journal-title":"Clin Cardiol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e044605","DOI":"10.1136\/bmjopen-2020-044605","article-title":"Left atrial pressure overload and prognosis in elderly patients with heart failure and preserved ejection fraction: a prospective multicenter observational study","volume":"11","author":"Hoshida","year":"2021","journal-title":"BMJ Open"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.21037\/atm-21-3561","article-title":"Pulmonary artery pressure is associated with mid-term major adverse cardiovascular events and postprocedure pericardial effusion in atrial fibrillation patients undergoing left atrial appendage occlusion","volume":"9","author":"Zou","year":"2021","journal-title":"Ann Transl Med"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.1188322\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T10:48:33Z","timestamp":1695034113000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.1188322\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,6]]},"references-count":23,"alternative-id":["10.3389\/fcvm.2023.1188322"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2023.1188322","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,6]]},"article-number":"1188322"}}